慢性粒细胞性白血病治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

慢性粒细胞性白血病治疗市场按治疗类型(靶向治疗、化疗、生物治疗等)、最终用户和地理位置进行细分。

慢性粒细胞白血病治疗市场快照

 Chronic Myelogenous Leukemia Treatment Market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.3 %
Chronic Myelogenous Leukemia Treatment Market Size

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

研究的慢性粒细胞白血病治疗市场预计在预测期内将以近 5.3% 的复合年增长率增长。导致市场增长的主要因素是慢性粒细胞性白血病 (CML) 的患病率增加。根据美国癌症协会 (ACS) 的 2019 年出版物,15% 的白血病病例是慢性粒细胞白血病。据估计,2019 年将有约 8,990 例新确诊 CML 病例,约 1,140 人将死于 CML。这一统计数据表明,有大量人群易患慢性粒细胞白血病,这可能直接影响 CML 市场的增长。此外,生物技术和制药公司对研发项目的投资不断增加,也推动了市场增长。然而,

报告范围

慢性粒细胞白血病是一种癌症,起源于骨髓的造血细胞并侵入血液。该报告按治疗类型和地理细分

By Treatment Type
Targeted therapy
Chemotherapy
Biologic therapy
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

化疗板块有望在预测期内保持其最高市场份额

  • 在慢性粒细胞白血病治疗市场中,化疗有望占据最高份额。几乎所有时候,癌症患者的手术和放射治疗都会去除、杀死或破坏某个区域的癌细胞,但化疗可以在整个身体中发挥作用并产生更好的效果。化疗对于杀死扩散到身体不同部位的癌细胞是必要的。相反,手术和放射仅攻击或杀死位于特定部位的肿瘤。由于慢性粒细胞白血病是一种癌症,大多数情况下,它会在短时间内扩散到全身,肿瘤学家选择进行化疗以获得更好的效果。 
  • 由于对并发症较少的治疗的偏好日益增加,预计生物疗法在预测期内也将快速增长。
Chronic Myelogenous Leukemia Treatment Market Share

北美在市场上占主导地位,预计在预测期内也会如此

在整个预测期内,预计北美将主导整个慢性粒细胞性白血病市场。市场增长是由于关键参与者的存在、该地区 CML 患者的高患病率、已建立的医疗保健基础设施以及品牌药物的可用性等因素,这些因素是其在市场上占有很大份额的一些关键因素。此外,有益的政府举措和研究合作伙伴数量的增加是预计增加市场增长的一些驱动因素。美国拥有最大的市场份额。美国在发达国家中拥有独特的医疗保健体系。但是,该国的医院成本非常高;政府或私人保险承保。

Chronic Myelogenous Leukemia Treatment Market Forecast

竞争格局

慢性粒细胞性白血病治疗市场竞争适度,由几个主要参与者组成。目前主导市场的一些公司是 Bristol-Myers Squibb Co.、Novartis AG、Pfizer Inc.、Takeda Pharmaceutical Co. Ltd.、Teva Pharmaceutical Industries Ltd.、Mylan NV、Merck & Co. Inc、F. Hoffmann -La Roche Ltd.、Boehringer Ingelheim International GmbH、Sanofi-Aventis。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 High Incidence and Prevalence of Chronic Myeloid Leukemia

      2. 4.2.2 Advancement in Drug Development

      3. 4.2.3 Increasing Investements in Research and Development

    3. 4.3 Market Restraints

      1. 4.3.1 Complications Related to Chemotherapy

      2. 4.3.2 Stringent Regulations on Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment Type

      1. 5.1.1 Targeted therapy

      2. 5.1.2 Chemotherapy

      3. 5.1.3 Biologic therapy

      4. 5.1.4 Others

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle-East and Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle-East and Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bristol-Myers Squibb Co.

      2. 6.1.2 Novartis AG

      3. 6.1.3 Pfizer Inc.

      4. 6.1.4 Takeda Pharmaceutical Co. Ltd.

      5. 6.1.5 Teva Pharmaceutical Industries Ltd.

      6. 6.1.6 Mylan NV

      7. 6.1.7 Merck & Co. Inc

      8. 6.1.8 F. Hoffmann-La Roche Ltd.

      9. 6.1.9 Boehringer Ingelheim International GmbH

      10. 6.1.10 Sanofi-Aventis

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Chronic Myelogenous Leukemia Treatment Market market is studied from 2018 - 2026.

The Chronic Myelogenous Leukemia Treatment Market is growing at a CAGR of 5.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Bristol-Myers Squibb Co, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd are the major companies operating in Chronic Myelogenous Leukemia Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!